Riskpilot← Back to searchSign inGet full accessSANDVIKA ØYELEGESENTER AS
ASActiveOrg 984266774Fjordalléen 18, 0250 OsloMedical specialists activities · NACE 8622Est. 20025 employeeswww.sanvika-oyelegesenter.no
Revenue 2024
NOK 10,1M
+7% vs 2023
EBITDA margin
2.9%
+27% vs 2023
Equity ratio
-99.6%
Financial strength
Net profit 2024
NOK 157K
+239% vs 2023
| Revenue | NOK 10,1M | +7% |
| EBITDA | NOK 291K | +27% |
| Net profit | NOK 157K | +239% |
| Total assets | NOK 1,3M | +3% |
| Equity | NOK -1,3M | +11% |
| Employees | 5 | — |
Legal name
SANDVIKA ØYELEGESENTER AS
Org number
984266774
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
28. februar 2002
Share capital
NOK 200 000
Employees
5 (FTE)
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Daglig leder og styrets leder i fellesskap.
Company purpose
Undersøke og behandle pasienter med øyesykdommer og deltagelse i andre virksomheter.
Address
Fjordalléen 18, 0250 Oslo
Phone
+4767566090
Email
post@sandvika-oyelegesenter.no
Website
www.sanvika-oyelegesenter.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 7 279 | 7 723 | 8 009 | 9 463 | 10 094 |
| Staff expenses | −1 595 | −1 571 | −1 740 | −1 723 | −1 885 |
| EBITDA | 917 | 501 | 1 256 | 230 | 291 |
| Depreciation & amort. | −48 | −84 | −42 | −42 | −42 |
| EBIT | 869 | 417 | 1 214 | 188 | 250 |
| Net financials | −86 | −112 | −108 | −129 | −48 |
| Profit before tax | 783 | 305 | 1 106 | 59 | 201 |
| Tax | 173 | −856 | 243 | 13 | 44 |
| Net profit | 610 | 1 161 | 863 | 46 | 157 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 4 492 | 1 534 | 1 201 | 1 225 | 1 267 |
| Equity | 1 076 | −2 328 | −1 465 | −1 419 | −1 262 |
| Long-term debt | 2 726 | 2 299 | 1 842 | 1 503 | 1 182 |
| Short-term debt | 690 | 1 563 | 824 | 1 141 | 1 347 |
| Total debt | 3 416 | 3 862 | 2 666 | 2 644 | 2 529 |
EBITDA margin
2.9%
This company
15.8%
Market median
-82% vs market
20202024
Equity ratio
-99.6%
This company
38.2%
Market median
-361% vs market
20202024
Return on equity
15706900.0%
This company
18.4%
Market median
+85363487% vs market
20202024
Net profit margin
1.6%
This company
8.1%
Market median
-80% vs market
20202024
Asset turnover
7.97×
This company
1.12×
Market median
+612% vs market
20202024
Debt / equity
2.00×
This company
0.62×
Market median
-223% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
ØF Chief Executive Officer | Chief Executive Officer | 2010 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Chairman | 2010 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 50% | 50% | 2024 | |
| Company | 25% | 25% | 2024 | |
| Individual | 25% | 25% | 2022 | |
| Company | 25% | 25% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Arenabre As
SANDVIKA ØYELEGESENTER AS Board members of SANDVIKA ØYELEGESENTER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Øyvind Fygd | Chief Executive Officer | 0 companies |
| Tore Tveter | Chairman | 0 companies |